MEI Pharma, Inc. MEIP
Set alert
3.07 USD 0.00 0.00%
At close · Sep 10
2.85 Day range 3.25
2.85 52-week range 3.25
- YTD
- +132.58%
- 1 year
- +132.58%
- Open
- 2.89
- Prev close
- 3.07
- Mkt cap
- 20.45M
- Vol
- 3.97M
- Avg vol
- 1.15M
- EPS
- -4.75
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.85
- High
- 3.25
- Forward P/E
- -0.64
- Beta
- 0.71
- Short ratio
- 0.94
- Inst. own
- 41.04%
- Dividend
- 0.00
- Ex-div date
- Nov 15, 2023
- Earnings
- Feb 11, 2025
- 50-d avg
- 2.83
- 200-d avg
- 3.10
- 1y target
- 0.00
2Y chart
Events in this range
- Sep 27, 2023Rating: Stifel · Hold → Hold
- Nov 9, 2023Earnings: 8.46; estimate -1.47; surprise 675.51%
- Nov 16, 2023Dividend: 1.75
- Feb 13, 2024Earnings: -1.66; estimate -1.46; surprise -13.7%
- Feb 14, 2024Rating: Stifel · Hold → Hold
- Apr 12, 2024Rating: Stifel · Hold → Hold
- May 9, 2024Earnings: -1.37; estimate -1.38; surprise 0.72%
- Jul 23, 2024Downgrade: Laidlaw & Co. · Buy → Hold
- Sep 19, 2024Earnings: -1.13; estimate -1.48; surprise 23.65%
- Nov 12, 2024Earnings: -1.2; estimate 0; surprise —%
- Feb 11, 2025Earnings: —; estimate 0; surprise —%
Signals (64)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Sep 10, 2025 | 1 year ago |
| SMA: Bearish | Sep 9, 2025 | 1 year ago |
| RSI: Oversold | Sep 8, 2025 | 1 year ago |
| SMA: Bearish | Sep 4, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 31, 2025 | 1 year ago |
| RSI: Overbought | Jul 15, 2025 | 1 year ago |
| SMA: Bullish | Jul 3, 2025 | 1 year ago |
| SMA: Bearish | Jun 30, 2025 | 1 year ago |
| SMA: Bullish | Jun 26, 2025 | 1 year ago |
| RSI: Overbought | Jun 26, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 25, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 20, 2025 | 1 year ago |
| SMA: Bullish | May 29, 2025 | 1 year ago |
| SMA: Bearish | May 28, 2025 | 1 year ago |
| SMA: Bullish | May 20, 2025 | 1 year ago |
| SMA: Bearish | May 16, 2025 | 1 year ago |
| SMA: Bullish | May 14, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 16, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 1, 2025 | 1 year ago |
| RSI: Oversold | Mar 31, 2025 | 1 year ago |
Newest 20 of 64.
Key statistics
- Market cap
- 15.72M
- Enterprise value
- -17.42M
- Trailing P/E
- 0.00
- Forward P/E
- -0.64
- PEG ratio
- 0.00
- Price / sales
- 0.24
- Price / book
- 0.48
- EPS (TTM)
- -6.99
- Beta
- 0.71
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 27.23%
- Revenue (TTM)
- 65.30M
- Revenue growth
- -100.00%
- Free cash flow
- 12.76M
- Total cash
- 38.34M
- Total debt
- 0
- Return on equity
- 61.68%
- Shares outstanding
- 6.66M
- Short % of float
- 1.48%
- 50-day average
- 2.83
- 200-day average
- 3.10
Analyst view
Consensus: none
Price target (mean) 0.00
Ratings (0m) 2 0 buy · 2 hold · 0 sell
- Strong buy0
- Buy0
- Hold2
- Sell0
- Strong sell0
Next earnings
Feb 11, 2025
Expected Feb 11, 2025. Consensus EPS estimate 0.00.
Financials — quick view
MEIP Revenue — quarterly 0
MEIP Net income — quarterly -2.57M
MEIP EPS — quarterly -0.39
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 11, 2025 | Dec 1, 2024 | 0.00 | — | — | — |
| Nov 12, 2024 | Sep 1, 2024 | 0.00 | -1.20 | — | — |
| Sep 19, 2024 | Jun 1, 2024 | -1.48 | -1.13 | +0.35 | +23.65% |
| May 9, 2024 | Mar 1, 2024 | -1.38 | -1.37 | +0.01 | +0.72% |
| Feb 13, 2024 | Dec 1, 2023 | -1.46 | -1.66 | -0.20 | -13.70% |
| Nov 9, 2023 | Sep 1, 2023 | -1.47 | 8.46 | +9.93 | +675.51% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 23, 2024 | Laidlaw & Co. | down | Buy | Hold |
| Apr 12, 2024 | Stifel | main | Hold | Hold |
| Feb 14, 2024 | Stifel | main | Hold | Hold |
| Sep 27, 2023 | Stifel | main | Hold | Hold |
| May 23, 2023 | Brookline Capital | main | Buy | Buy |
| May 12, 2023 | Stifel | main | Hold | Hold |
About MEI Pharma, Inc.
MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. It develops ME-344, an intravenous small molecule inhibitor mitochondrial oxidative phosphorylation to treat human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and solid tumors. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- meipharma.com
News
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Why Robinhood Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Friday's After-Market Session
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- 12 Health Care Stocks Moving In Friday's Intraday Session
- Dow Falls Over 200 Points; 3M Earnings Top Views
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Why CrowdStrike Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- Why Domino's Pizza Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Your note
Sign in to keep a note on MEIP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANSON FUNDS MANAGEMENT L.P. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Oct 19, 2023 | 0 |
| BALTIC CHARLES V III | Director | Purchase | Feb 27, 2023 | 111,100 |
| FLYNN JAMES P | Director | Stock Award(Grant) | May 15, 2024 | 7,900 |
| WOOD STEVEN D | Director | Stock Award(Grant) | May 16, 2024 | 72,092 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Anson Funds Management LP | 16.41% | 1,093,183 | 2.58M | Sep 29, 2024 |
| Cable Car Capital LLC | 9.18% | 611,440 | 1.44M | Sep 29, 2024 |
| Vanguard Group Inc | 5.79% | 385,728 | 910.32K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 2.07% | 137,646 | 324.84K | Sep 29, 2024 |
| Acadian Asset Management. LLC | 1.99% | 132,362 | 312.37K | Sep 29, 2024 |
| Blackrock Inc. | 1.01% | 67,260 | 158.73K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.02% | 201,106 | 474.61K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.19% | 79,554 | 187.75K | Sep 29, 2024 |
| Vanguard Explorer Fund, Inc. | 0.92% | 61,621 | 145.43K | Jul 30, 2024 |
| Vanguard Variable Insurance Fund-Small Company Growth | 0.55% | 36,960 | 87.22K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.54% | 35,708 | 84.27K | Oct 30, 2024 |
| Delaware Group Equity Fds IV-Delaware Healthcare Fund | 0.45% | 30,000 | 70.80K | Sep 29, 2024 |